Ameriprise Financial Inc. Has $3.18 Million Holdings in NewLink Genetics Corp (NLNK)

Ameriprise Financial Inc. raised its holdings in shares of NewLink Genetics Corp (NASDAQ:NLNK) by 207.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 311,927 shares of the biotechnology company’s stock after purchasing an additional 210,360 shares during the period. Ameriprise Financial Inc. owned 0.84% of NewLink Genetics worth $3,176,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. The Manufacturers Life Insurance Company increased its stake in shares of NewLink Genetics by 3.0% during the second quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock valued at $140,000 after purchasing an additional 556 shares in the last quarter. Advisor Group Inc. increased its stake in shares of NewLink Genetics by 3.4% during the second quarter. Advisor Group Inc. now owns 18,082 shares of the biotechnology company’s stock valued at $133,000 after purchasing an additional 600 shares in the last quarter. First Trust Advisors LP increased its stake in shares of NewLink Genetics by 11.1% during the second quarter. First Trust Advisors LP now owns 28,598 shares of the biotechnology company’s stock valued at $210,000 after purchasing an additional 2,859 shares in the last quarter. Wells Fargo & Company MN increased its stake in shares of NewLink Genetics by 1.8% during the second quarter. Wells Fargo & Company MN now owns 165,791 shares of the biotechnology company’s stock valued at $1,219,000 after purchasing an additional 2,865 shares in the last quarter. Finally, State Street Corp increased its stake in shares of NewLink Genetics by 1.2% during the second quarter. State Street Corp now owns 391,464 shares of the biotechnology company’s stock valued at $2,875,000 after purchasing an additional 4,630 shares in the last quarter. 52.63% of the stock is owned by institutional investors and hedge funds.

Several brokerages recently weighed in on NLNK. Zacks Investment Research raised shares of NewLink Genetics from a “hold” rating to a “buy” rating and set a $9.00 price target for the company in a research report on Wednesday. ValuEngine downgraded shares of NewLink Genetics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 26th. Jefferies Group raised shares of NewLink Genetics from a “hold” rating to a “buy” rating and raised their price target for the company from $7.00 to $26.00 in a research report on Friday, September 8th. Cantor Fitzgerald restated a “buy” rating and issued a $26.00 target price on shares of NewLink Genetics in a report on Monday, September 25th. Finally, Stifel Nicolaus raised their target price on shares of NewLink Genetics from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Friday, November 3rd. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. NewLink Genetics presently has a consensus rating of “Buy” and an average price target of $23.29.

In other NewLink Genetics news, major shareholder Stine Seed Farm, Inc. purchased 780,487 shares of the company’s stock in a transaction dated Friday, October 6th. The shares were acquired at an average price of $10.25 per share, for a total transaction of $7,999,991.75. Following the purchase, the insider now directly owns 7,857,732 shares of the company’s stock, valued at approximately $80,541,753. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 13.70% of the company’s stock.

NewLink Genetics Corp (NASDAQ:NLNK) opened at $9.10 on Thursday. The firm has a market cap of $329.62, a price-to-earnings ratio of -3.73 and a beta of 1.10. NewLink Genetics Corp has a one year low of $5.90 and a one year high of $25.17.

WARNING: This story was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.chaffeybreeze.com/2018/01/04/ameriprise-financial-inc-has-3-18-million-holdings-in-newlink-genetics-corp-nlnk.html.

NewLink Genetics Profile

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Want to see what other hedge funds are holding NLNK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NewLink Genetics Corp (NASDAQ:NLNK).

Institutional Ownership by Quarter for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply